| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 26th January 2021 | Inc. Innoviva, | 1,867,912 | Open or private purchase | $3.25 | $6,070,714.00 |
| 15th January 2021 | Manoussos Perros | 79,750 | Grant/award etc. | $0.00 | |
| 15th January 2021 | Matthew Ronsheim | 25,000 | Grant/award etc. | $0.00 | |
| 15th January 2021 | John Patrick Mueller | 25,000 | Grant/award etc. | $0.00 | |
| 15th January 2021 | Elizabeth M Keiley | 25,000 | Grant/award etc. | $0.00 | |
| 15th January 2021 | David Altarac | 25,000 | Grant/award etc. | $0.00 | |
| 1st September 2020 | Inc. Innoviva, | 4,672,897 | Open or private purchase | $2.68 | $12,499,999.48 |
| 11th June 2020 | Inc. Innoviva, | 12,677,490 | Open or private purchase | $2.50 | $31,693,725.00 |
| 27th March 2020 | Inc. Innoviva, | 7,717,661 | Open or private purchase | $2.87 | $22,149,687.07 |
| 4th February 2020 | Life Sciences Viii, L.P. Frazier | 6,360,272 | Conversion of derivative | $0.00 |
Entasis Therapeutics Holdings
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections.
Ticker: ETTX
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1724344
Employees: 33
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $51 M (0%)
Other Assets, Current: $1 M (-49%)
Assets, Current: $55 M (11%)
Property, Plant and Equipment, Net: $267 Th (-22%)
Other Assets, Noncurrent: $63 Th (0%)
Assets: $56 M (10%)
Accounts Payable, Current: $2 M (22%)
Liabilities, Current: $6 M (-18%)
Liabilities: $7 M (-19%)
Common Stock, Value, Issued: $27 Th (107%)
Common Stock, Shares, Issued: $27 M (105%)
Additional Paid in Capital, Common Stock: $212 M (20%)
Retained Earnings (Accumulated Deficit): $163 M (21%)
Stockholders' Equity (Parent): $49 M (0%)
Liabilities and Equity: $56 M (10%)
Research and Development: $10 M (-53%)
General and Administrative Expenses: $3 M (-53%)
Operating Income/Loss: $13 M (-53%)
Provision for income taxes: $73 Th (-49%)
